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MaOBJECTIVES The aim of this study was to develop a prediction model to identify patients with low-risk Staphylococcus
aureus bacteremia (SAB), in whom infective endocarditis (IE) can be ruled out based on transthoracic echocardiogram
(TTE).
BACKGROUND S. aureus is a major cause of bacteremia and often leads to IE. Current guidelines recommend per-
forming transesophageal echocardiography on all patients or treating all patients empirically with prolonged intravenous
antibiotics; however, this approach is resource intensive, many physicians do not adhere to guidelines, and recent studies
suggest that low-risk patients may not require transesophageal echocardiography.
METHODS We conducted a retrospective cohort study of 833 consecutive hospitalized patients with SAB from 7
academic and community hospitals in Toronto, Canada, over a 3-year period (2007 to 2010). Patients who received a TTE
within 28 days of bacteremia (n ¼ 536) were randomly divided into derivation and validation cohorts. Multivariable
logistic regression analysis was used to determine high-risk criteria for IE in the derivation cohort, and criteria were then
applied to the validation cohort to determine diagnostic properties.
RESULTS Four high-risk criteria predicted IE: indeterminate or positive TTE (p < 0.001), community-acquired bacter-
emia (p ¼ 0.034), intravenous drug use (p < 0.001), and high-risk cardiac condition (p < 0.004). In the validation
cohort, the presence of any 1 of the high-risk criteria had 97% sensitivity (95% conﬁdence interval [CI]: 87% to 100%)
and 99% negative predictive value (95% CI: 96% to 100%) for IE. The negative likelihood ratio was 0.05 (95% CI: 0.007
to 0.35).
CONCLUSIONS A normal TTE ruled out IE in patients without community-acquired SAB, high-risk cardiac conditions,
and intravenous drug use. This study provides evidence that clinical risk stratiﬁcation combined with a normal TTE
may be adequate to rule out IE in most patients with SAB. (J Am Coll Cardiol Img 2015;8:924–31) © 2015 by the
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
IE = infective endocarditis
IQR = interquartile range
MRSA = methicillin-resistant
Staphylococcus aureus
SAB = Staphylococcus aureus
bacteremia
TEE = transesophageal
echocardiogram
TTE = transthoracic
cardiography
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925S taphylococcus aureus is a major cause of bacter-emia and commonly leads to severe complica-tions (1–3). Infective endocarditis (IE) occurs
in up to 25% of cases and is associated with lengthy
hospitalization, relapsing bacteremia, and high mor-
tality (3–9). Identiﬁcation of IE is crucial because
patients require a more complex approach to manage-
ment, which includes prolonged use of intravenous
antibiotic therapy (10,11). The majority of patients
with IE do not have clinically evident disease at the
time of bacteremia, which makes early diagnosis chal-
lenging (4,8,12).
Current guidelines for management of S. aureus
bacteremia (SAB) assume IE, requiring at least 4
weeks of intravenous antibiotic therapy unless a
transesophageal echocardiogram (TEE) is negative
(13). This is based on historical studies demonstrating
that transthoracic echocardiography (TTE) may not be
sufﬁciently sensitive to rule out IE (4). However,
performing a TEE on all patients is resource intensive,
and clinicians frequently deviate from current
guidelines according to TEE availability, patient
refusal, and comorbid critical illness (8,14,15).SEE PAGE 932Modern echocardiographic techniques and equip-
ment have improved TTE sensitivity in SAB, particu-
larly in low-risk patients (16–18). TTE might therefore
exclude IE in many patients and eliminate the
need for more invasive testing with TEE (19).
Thus, we sought to describe the current use ofFIGURE 1 Flow Diagram of Patients With Staphylococcus aureus Bac
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Exclusion Criteria:
- Age < 18: n = 163
- Transfer/left AMA  48 hrs: n = 27
- Death/palliation  48 hrs: n = 113
   * 2 patients met more than 1
      exclusion criteria
AMA ¼ against medical advice; TEE ¼ transesophageal echocardiogram;echocardiography in a multicenter SAB co-
hort in Toronto, Canada. We then tested the
potential of a multivariable model to identify
low-risk patients, in whom IE can be ruled
out based on TTE alone.
METHODS
PATIENTS AND SETTING. We conducted our
study at 7 university-afﬁliated and commu-
nity hospitals in the Greater Toronto area.
The 7 sites accounted for a total of 3,338 acute
care beds and approximately 160,000 annual
patient admissions. We obtained approval from the
research ethics boards at all sites. We retrospectively
identiﬁed all inpatients with at least 1 positive blood
culture for S. aureus from each hospital’s microbi-
ology laboratory information system during a 3-year
period from April 1, 2007, through March 31, 2010.
Five microbiology laboratories provided results for
the 7 study sites. All sites used standard methods that
conformed to Clinical and Laboratory Standards
Institute guidelines for S. aureus identiﬁcation and
antimicrobial susceptibilities (20).
We included only adult inpatients (age $18 years)
with a ﬁrst SAB episode and excluded patients who
died, were deemed suitable for palliative care only,
were transferred to another facility, or left against
medical advice within 48 h of bacteremia. We entered
each patient in the study only once, using the ﬁrst
positive blood culture as the index isolate. Request
echoteremia, Including Type of Echocardiography Performed
cluded:
 = 833
Neither
n = 267
Both
n = 90
ive blood culture for S. aureus
 = 1134
ed within 28 days of bacteremia
Mount Sinai Hospital (n = 119)
North York General Hospital (n = 81)
Sunnybrook Health Sciences Center (n = 224)
Toronto General Hospital (n = 172)
Toronto Western Hospital (n = 115)
Trillium Health Center (n = 122)
TTE ¼ transthoracic echocardiogram.
TABLE 1 Characteristics of Patients With SAB, by Type of Echocardiogram
Echocardiogram Status
No Echocardiogram
(n ¼ 267)
TTE Only
(n ¼ 449)
TEE Only
(n ¼ 27)
TTE and TEE
(n ¼ 90)
Age, yrs 64 (52–79) 66 (52–79) 53 (45–64) 60.5 (49–71)
Female 90 (34) 169 (38) 10 (37) 30 (33)
Admitting service
Medical 140 (52) 303 (67) 11 (41) 54 (60)
Surgical 77 (29) 88 (20) 9 (33) 17 (19)
ICU 50 (19) 58 (13) 7 (26) 19 (21)
Location of acquisition*
Community-acquired 47 (18) 135 (31) 7 (26) 41 (46)
Health care-associated 102 (38) 172 (38) 6 (22) 27 (30)
Nosocomial 112 (43) 134 (30) 14 (52) 21 (24)
Risk factors for complicated SAB
High-risk cardiac condition 15 (5.6) 35 (7.8) 6 (22) 14 (16)
Intravenous drug use 5 (1.9) 27 (6.0) 2 (7.4) 7 (7.8)
Hemodialysis 21 (7.9) 52 (12) 2 (7.4) 14 (16)
MRSA 50 (19) 71 (16) 7 (26) 14 (16)
Early infectious foci†
Intravascular catheter 48 (18) 77 (17) 6 (22) 15 (17)
Skin/soft tissue 61 (23) 92 (20) 3 (11) 18 (20)
Bone or joint 27 (10) 80 (18) 3 (11) 21 (23)
Respiratory 47 (18) 75 (17) 6 (22) 20 (22)
Endovascular 7 (2.6) 23 (5.1) 3 (11) 5 (5.6)
Unknown 67 (25) 107 (24) 8 (30) 23 (26)
Other 49 (18) 97 (22) 4 (15) 28 (31)
Febrile at 72 h 42 (16) 47 (10) 6 (22) 20 (22)
Repeat blood cultures 2 to 4 days
after initial positive culture‡
Positive 15 (5.6) 52 (12) 1 (3.7) 22 (24)
Negative 55 (21) 122 (27) 6 (22) 30 (33)
Not performed 183 (69) 258 (57) 17 (63) 33 (37)
ID consultation within 7 days 125 (47) 292 (65) 22 (81) 59 (66)
Antibiotic duration, days§ 14 (6–27) 19 (14–32) 17 (9–35) 29.50 (16–45)
IE within 90 days 4 (2) 40 (9) 7 (26) 25 (28)
Mortality within 90 days 76 (28) 91 (20) 5 (19) 23 (26)
Follow-up, days 15 (7–32) 23 (11–43) 26 (17–37) 29 (16–54)
Values are median (interquartile range) or n (%). *Location of acquisition was not available for 15 patients (1.8%).
†Documented infectious foci within 10 days of SAB, excluding IE. Some patients had >1 infectious focus. Data
were not available for 16 patients (1.9%). ‡Data were not available for 39 patients (4.7%). §Data were not
available for 40 patients (4.8%).
ICU ¼ intensive care unit; ID ¼ infectious disease; IE ¼ infective endocarditis; MRSA ¼ methicillin-resistant
Staphylococcus aureus; SAB ¼ Staphylococcus aureus bacteremia; TEE ¼ transesophageal echocardiogram;
TTE ¼ transthoracic echocardiogram.
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926for echocardiography was at the discretion of the
primary responsible physician. All echocardiograms
were reported by cardiologists, except at 1 site where
intraoperative TEEs were read by National Board of
Echocardiography–certiﬁed anesthesiologists. A vari-
ety of different echocardiography machines were
used at the 7 sites.
Infectious disease services consultation was avail-
able at all hospital sites. At 3 hospitals, the microbi-
ology laboratory notiﬁed the infectious diseases
service when inpatient blood cultures were positive
for S. aureus. Departmental policy at these hospitalsincluded the offering of a consultation for patients
admitted to general internal medicine or the medical-
surgical intensive care unit and automatic perfor-
mance of a consultation for patients admitted to all
other services.
DATA COLLECTION AND VERIFICATION. We abstracted
data from electronic and paper medical records using
a standardized electronic case report form designed
by a multidisciplinary team. The recorded data in-
cluded patient demographics, comorbidities, micro-
biological data, and inpatient antibiotic treatment
and investigations, as well as clinical outcomes that
occurred within 90 days of initial bacteremia. We
independently conducted source data veriﬁcation
by assessing a random sample of 10% of data entry
points for accuracy, and we performed range edits
and value checks to reduce the potential for data
entry errors. We referred data gaps and suspected
anomalies back to hospital sites for veriﬁcation. Data
were deemed high quality and near complete.
DEFINITIONS. We classiﬁed bacteremia as nosoco-
mial, health care–associated, or community-acquired
according to standard deﬁnitions (20,21). Patients
had prolonged bacteremia when repeat blood cul-
tures performed 2 to 4 days after initial bacteremia
were positive for S. aureus. High-risk cardiac condi-
tions were deﬁned as prosthetic heart valve or pros-
thetic material used for cardiac valve repair,
congenital heart disease, cardiac transplantation with
valvulopathy, history of prior endocarditis, and
presence of a pacemaker or automatic implantable
cardioverter-deﬁbrillator (22). We deﬁned IE accord-
ing to the modiﬁed Duke criteria (22).
Echocardiographic ﬁndings that fulﬁlled major
Duke criteria included the presence of an oscillating
intracardiac mass, perivalvular leak, or abscess (4).
We classiﬁed TTE as indeterminate when docu-
mented abnormalities that did not fulﬁll the above
criteria were present, including new or signiﬁcantly
worsening valvular regurgitation, abnormal valvular
thickening, abnormal nonoscillatory echogenic focus,
or any abnormality for which TEE was speciﬁcally
recommended for further evaluation. We also
classiﬁed as indeterminate any echocardiogram
that demonstrated suboptimal views because of
technical difﬁculties, was noted to be of poor quality,
or was characterized as a limited study for an alter-
nate indication. Normal TTEs had no documented
major Duke criteria features or indeterminate fea-
tures. In patients who received multiple TTEs,
we categorized patients in the multivariable model
according to the ﬁrst TTE performed within 28 days
of bacteremia.
TABLE 2 Baseline Characteristics of Derivation and Validation Cohorts
Derivation Cohort
(n ¼ 268)
Validation Cohort
(n ¼ 268) p Value
Age, yrs 64 (49–77) 66 (52–78) 0.21
Female 100 (37) 98 (37) 0.93
Admitting service
Medical 174 (65) 181 (68)
Surgical 51 (19) 53 (20) 0.54
ICU 43 (16) 34 (13)
Location of acquisition*
Community-acquired 90 (34) 84 (31)
Health care-associated 97 (37) 102 (39) 0.85
Nosocomial 77 (29) 77 (29)
Risk factors for complicated SAB
High-risk cardiac condition 18 (6.7) 30 (11) 0.10
Intravenous drug use 17 (6.3) 17 (6.3) >0.99
Hemodialysis 38 (14) 27 (10) 0.19
MSSA 222 (83) 229 (85) 0.48
MRSA 46 (17) 39 (15)
Early infectious foci†
Intravascular catheter 44 (16) 48 (18) 0.70
Skin/soft tissue 53 (20) 57 (21) 0.68
Bone or joint 54 (20) 45 (17) 0.41
Respiratory 54 (20) 40 (15) 0.12
Endovascular 16 (6.0) 12 (4.5) 0.56
Unknown 63 (24) 67 (25) 0.76
Other 66 (25) 57 (21) 0.36
Early clinical course
Febrile at 72 h 35 (13) 31 (12) 0.59
Repeat blood cultures 2–4 days
after initial positive culture‡
Positive 33 (12) 39 (15)
Negative 81 (30) 71 (26) 0.53
Not performed 142 (53) 148 (55)
ID consultation within 7 days 181 (68) 169 (63) 0.32
Echocardiogram
TTE and TEE 45 (17) 44 (16) >0.99
TTE result
Normal 187 (70) 181 (68)
Indeterminate 57 (21) 61 (23) 0.86
Positive 24 (9.0) 26 (9.7)
Antibiotic duration, days§ 21 (14–38) 20 (13–32) 0.21
IE within 90 days 26 (9.7) 38 (14) 0.14
Mortality within 90 days 56 (21) 55 (21) >0.99
Follow-up, days 25 (13–45) 25 (12–44) 0.83
Values are median (interquartile range) or n (%). *Location of acquisition was not available for 9 patients (1.7%).
†Documented infectious foci within 10 days of SAB, excluding IE. Some patients had >1 infectious focus. Data
were not available for 7 patients (1.3%). ‡Data were not available for 22 patients (4.1%). §Data were not available
for 10 patients (1.9%).
MSSA ¼ methicillin-sensitive Staphylococcus aureus; other abbreviations as in Table 1.
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927OUTCOMES. The primary outcome was diagnosis
of IE within 90 days of SAB. The secondary outcome
was SAB relapse with an identical antimicrobial sus-
ceptibility pattern that occurred >14 days after initial
positive blood culture.
STATISTICAL ANALYSIS. Descriptive analysis included
median (interquartile range [IQR]) for continuous
variables and number (percentage) for categorical
variables. We compared continuous variables using
the Student t test or Wilcoxon rank-sum test. We used
the chi-square or Fisher exact test to compare cate-
gorical variables.
Patients who received a TTE within 28 days of
bacteremia were randomized in a 1:1 ratio into a
derivation or validation cohort. In the derivation
cohort, we used a multivariable logistic regression
model to identify predictors of endocarditis along
with initial TTE result. In the logistic model, endo-
carditis was the dependent variable. Initial TTE
result was an independent variable along with other
potential predictors, including community-acquired
infection, high-risk cardiac condition, hemodialysis,
intravenous drug use, methicillin-resistant Staphy-
lococcus aureus (MRSA) bacteremia, intravenous
catheter infection, fever, and prolonged bacteremia.
We used several methods to conﬁrm the ﬁnal
multivariable logistic regression model of signiﬁcant
predictors, including univariate selection based on
p value, full model with all predictors, and both
forward and backward stepwise regression based
on Akaike information criterion and likelihood
ratio test.
In the validation cohort, we used signiﬁcant pre-
dictors in the ﬁnal multivariable regression model as
a clinical prediction rule for endocarditis. In deter-
mining diagnostic properties, we used our clinical
prediction rule as the test and endocarditis as the
criterion standard. We calculated sensitivity, speci-
ﬁcity, and predictive values with 95% conﬁdence in-
tervals (CIs) using the Wilson method. For likelihood
ratios, we calculated the 95% CI according to the
method described by Simel et al. (23).
All reported CIs were 2-sided 95% intervals, and all
tests were 2-sided with a p < 0.05 signiﬁcance level.
All analyses were performed with R version 3.0.1
(R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
We identiﬁed 1,134 consecutive inpatients with ﬁrst-
episode SAB; 833 met inclusion criteria (Figure 1).
Bacteremia was community acquired in 230 patients(27.6%), health care–associated in 307 patients
(36.9%), and nosocomial in 281 patients (33.7%).
S. aureus was methicillin resistant (MRSA) in 142 pa-
tients (17.0%). Seventy patients (8.4%) had a high-
risk cardiac condition.
Within 28 days of the ﬁrst positive blood culture
for S. aureus, 449 patients (53.9%) received a TTE
TABLE 3 Final Multi
Cohort, n ¼ 268)
Indeterminate or positi
Intravenous drug use
High-risk cardiac condi
Community-acquired*
*Bacteremia was considere
could not be conﬁrmed.
CI ¼ conﬁdence interval
TABLE 4 Diagnostic Properties of Multivariable Model in the
Validation Cohort (n ¼ 268)
True positive 37
False positive 110
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928alone, performed a median of 4 days (IQR: 2 to 6
days) after the initial positive blood culture. An
additional 90 patients (10.8%) received both TTE
and TEE, performed a median of 2 days (IQR: 2 to 4
days) and 8 days (IQR: 5 to 11 days) after initial
positive culture, respectively. Only 27 patients
(3.2%) received a TEE alone, a median of 6 days
(IQR: 4 to 12.5 days) after initial positive culture
(Table 1). Echocardiography was more likely to be
performed in patients with community-acquired
bacteremia (p < 0.001) or prolonged bacteremia
(p ¼ 0.007) and in those who received an infectious
disease consultation (p < 0.001). Patients admitted
to a medical service received echocardiography
more often than those admitted to a surgical service
(p ¼ 0.002).
Of 536 patients with a reported TTE within 28 days
of SAB, 368 (68.7%) had a normal echocardiogram.
Fifty patients (9.3%) had a TTE that fulﬁlled major
echocardiographic Duke criteria, and 118 patients
(22.0%) had an indeterminate TTE. IE was diagnosed
in 76 patients (9.1%) in the entire cohort and in 64
patients (11.9%) in the group receiving TTE. Median
duration of documented follow-up in patients
receiving TTE was 29 days (IQR: 13 to 50 days),
excluding patients who died within 30 days of
bacteremia.
There were 268 patients in each of the derivation
and validation cohorts. The cohorts had similar
baseline characteristics (Table 2). Indeterminate or
positive TTE, high-risk cardiac conditions, intrave-
nous drug use, and community-acquired bacteremia
were statistically signiﬁcant predictors of IE in uni-
variate analysis and were therefore used in devel-
oping the ﬁnal multivariable model (Table 3).
Hemodialysis (p ¼ 0.49), MRSA (p ¼ 0.38), non-
intravenous catheter focus (p ¼ 0.40), fever at 72 h (p
¼ 0.20), and prolonged bacteremia (p ¼ 0.73) were not
signiﬁcant IE predictors. Patients who met any pre-
diction criteria were considered at high risk for IE,
and all others were at low risk.variable Model Predictive for Infective Endocarditis (Derivation
OR (95% CI)
OR
p Value
Likelihood Ratio
p Value
ve TTE 20.56 (6.61–84.64) <0.001 <0.001
14.31 (3.32–70.15) <0.001 <0.001
tion 8.73 (2.10–36.02) 0.002 0.004
3.15 (1.09–9.45) 0.035 0.034
d to not be community-acquired in 4 patients in whom the location of acquisition
; OR ¼ odds ratio; TTE ¼ transthoracic echocardiogram.On the basis of the multivariable model criteria, 147
patients (55%) were at high risk for IE and 121 (45%)
were at low risk in the validation cohort. Multivari-
able model criteria had a sensitivity of 97% for IE and
a speciﬁcity of 52%. The negative predictive value for
IE was 99%, and the positive predictive value was
25% (Table 4). Only 1 patient with IE was considered
at low risk. The negative likelihood ratio was 0.05
(95% CI: 0.007 to 0.35). The prevalence of IE in the
validation cohort was 14.2%. Patients who met more
than 1 multivariable model criterion were at higher
risk for IE (Figure 2). Almost all patients with IE were
diagnosed within 10 days of initial positive blood
culture (Figure 3).
SAB relapse with MRSA occurred in 3 patients who
met low-risk criteria, all in the derivation cohort. Two
of 3 patients were already receiving antibiotic therapy
at the time of relapse, and 1 patient relapsed after
completing more than 5 weeks of treatment. All had
noncardiac deep-space or persistent infectious foci.
Endocarditis was ruled out on TEE in 1 patient,
whereas the other 2 had normal serial TTEs without
conﬁrmatory TEE. No patient in the validation cohort
experienced SAB relapse.DISCUSSION
We evaluated 833 consecutive inpatients with SAB
who received echocardiography at 7 community and
academic hospitals. Using a split derivation and
validation cohort, we found that a normal TTE ruled
out IE in patients without community-acquired SAB,
high-risk cardiac conditions, and intravenous drug
use. Our criteria were 97% sensitive for IE, with a
negative predictive value of 99% in a population withTrue negative 120
False negative 1
Sensitivity, % 97 (87–100)
Speciﬁcity, % 52 (46–59)
Positive predictive value, % 25 (19–33)
Negative predictive value, % 99 (96–100)
Positive likelihood ratio 2 (1.8–2.4)
Negative likelihood ratio 0.05 (0.007–0.35)
Values are n or % (95% conﬁdence interval). Prevalence of infective endocarditis
in the validation cohort was 14.2%.
False negative ¼ low-risk patient with infective endocarditis; False positive ¼
high-risk patient without infective endocarditis; True negative ¼ low-risk patient
without infective endocarditis; True positive ¼ high-risk patient with infective
endocarditis.
FIGURE 2 Frequency of Infective Endocarditis by Number of
Positive Criteria in the Validation Cohort (n ¼ 268)
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The 4 criteria include: 1) indeterminate or positive transthoracic
echocardiogram; 2) intravenous drug use; 3) high-risk cardiac
condition; and 4) community-acquired bacteremia. Error bars
indicate 95% conﬁdence intervals.
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92914.2% IE prevalence. Speciﬁcity was lower (52%),
possibly because of the stringent requirements for a
normal TTE. On the basis of our ﬁndings, we propose
that our combined clinical and TTE criteria are sufﬁ-
cient to rule out IE in a sizeable proportion of patients
with SAB. The use of this approach eliminated
the need for a TEE in almost one-half of theseFIGURE 3 Duke Criteria Fulﬁlled for Cases of Infective Endocarditis
)95=n(*enilesabtadesongaiD
L2 major
n = 47
1 major
n = 12
5 minor
n = 0
2 m
n 
TTE+
n = 5
TEE+
n = 1
Endocardial
n = 5†
Culture +
n = 7
*Baseline diagnosis of infective endocarditis occurred within 10 days of
transthoracic echocardiogram (TTE) and a positive transesophageal echopatients (45%), while missing IE in only 0.4% of those
screened.
Few studies using modern echocardiography have
examined a model with clinical and TTE criteria (19).
All were small or single-center studies, and none used
separate derivation and validation cohorts (17,18,24).
In a 2009 to 2010 study, Rasmussen et al. (17)
concluded that TTE may be an adequate screening
tool in patients at low risk for IE; however, criteria
were complex and based on many variables, which
introduces model instability. In another small study
from 2006 to 2011, IE was rare in patients without
prosthetic cardiac devices who had no valvular
regurgitation on echocardiogram (24). In an older
single-center study, patients without prosthetic
cardiac material, TTE evidence of regurgitation,
and clinical embolic phenomena had a <2% post-test
probability of IE (18). Our study supports the
role of TTE in risk stratiﬁcation, although our
clinical predictors and deﬁnition of normal TTE
differed (18,19,24).
In contrast to other recent studies of nosocomial
SAB, we demonstrate that TTE combined with simple
clinical risk criteria is useful to rule out IE in
SAB acquired from any location. Although 5 high-risk
criteria had >97% sensitivity and >99% negative pre-
dictive value for IE in nosocomial SAB (14), diagnostic
properties were less robust when these criteria were
applied to a prospective cohort that also included
community–acquired and health care–associated SAB
(15). Khatib and Sharma (15) found evidence of IE in
only 0.4% of patients with uncomplicated SAB,in the Derivation and Validation Cohorts
)5=n(*enilesabtadesongaidnU
ate diagnosis < 90 days (n = 5)
ajor
= 4
1 major
n = 1
5 minor
n = 0
No diagnosis
(n = 0)
Endocardial
n = 0
Culture +
n = 1
initial positive blood culture. †One patient had both a positive
cardiogram (TEE).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: All
patients with SAB should be evaluated for IE. Signiﬁ-
cant predictors of IE include intravenous drug use,
high-risk cardiac conditions, and community-acquired
bacteremia. In patients without these risk factors, a
normal transthoracic echocardiogram has a high
negative predictive value for endocarditis.
TRANSLATIONAL OUTLOOK: Adherence to pub-
lished SAB guidelines is poor. The implementation of
an endocarditis risk-stratiﬁcation model as part of a
broader SAB policy initiative should be evaluated in
prospective studies.
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930deﬁned on the basis of clinical criteria; however, the
majority did not receive any form of cardiac imaging
(14,15), and other studies with higher rates of echo-
cardiography utilization do not support the use of
clinical predictors alone to rule out IE (8,12,19).
Our study has several strengths. We examined a
large SAB cohort from 7 diverse hospital sites,
whereas most studies are limited to single hospital
centers (15,18,24). Furthermore, all patients included
in our multivariable model received at least 1 echo-
cardiogram, in contrast to other large cohorts in
which the majority did not receive cardiac imaging
(9,14). Patient charts were reviewed for 90 days after
the initial bacteremia episode, and follow-up was
documented for a median of 29 days. Finally, our
cohort included patients who acquired SAB from
different locations, including community-acquired,
health care–associated, and nosocomial settings.
STUDY LIMITATIONS. Our study has limitations that
merit mention. We obtained patient information by
reviewing hospital charts retrospectively, which has
inherent limitations. Our derivation and validation
cohorts excluded the 267 patients who did not receive
cardiac imaging. This represents potential selection
bias, because we observed differences in patients who
received echocardiography compared with the group
who did not: patients who did not receive echocardi-
ography had lower rates of community-acquired
bacteremia, intravenous drug use, prolonged bacter-
emia, and infectious disease consultation and were
more likely to be admitted to surgical services. Only a
minority of patients undergoing TTE also received a
TEE (16.7% in 28 days). Eighty patients (15%) received
serial TTEs, at a median of 18.5 days (IQR: 9 to 34 days)
after initial TTE, which may have increased detection
of IE cases through follow-up of patients over time.
Although no patient who satisﬁed all negative predic-
tion criteria was readmitted to the hospital with IE, we
cannot exclude the possibility that patients sought
medical attention at a health care facility other than
the original admitting hospital; however, 3 hospital
sites share a single microbiology laboratory, and pre-
vious work has demonstrated that most patients in
Toronto who are readmitted soon after dischargereturn to the same hospital (25). Moreover, the preva-
lence of IE in our populationwas similar to that of other
large unselected SAB cohorts, which suggests that we
did not miss signiﬁcant numbers of patients with
IE (6,9,14,24,26).
CONCLUSIONS
In our multicenter SAB cohort, a normal TTE ruled out
IE in patients without community-acquired SAB,
intravenous drug use, and high-risk cardiac condi-
tions. Our criteria provide evidence that in low-risk
patients with SAB, a TTE is adequate to exclude IE,
which could decrease the use of invasive tests and
provide more efﬁcient patient care.
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